Shares of Jyong Biotech Ltd. (NASDAQ:MENS - Get Free Report) fell 12.3% during trading on Wednesday . The stock traded as low as $2.42 and last traded at $2.42. 301,403 shares changed hands during trading, a decline of 34% from the average session volume of 458,348 shares. The stock had previously closed at $2.76.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a "sell (e+)" rating on shares of Jyong Biotech in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Sell".

Read Our Latest Report on Jyong Biotech

Jyong Biotech Trading Down 12.3%

The stock's 50-day moving average is $2.90 and its 200-day moving average is $30.25.

Jyong Biotech (NASDAQ:MENS - Get Free Report) last released its quarterly earnings data on Friday, January 9th. The company reported ($0.01) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Jyong Biotech

A number of large investors have recently modified their holdings of MENS. China Universal Asset Management Co. Ltd. acquired a new position in Jyong Biotech during the 4th quarter worth approximately $49,000. Man Group plc acquired a new position in shares of Jyong Biotech during the fourth quarter worth $56,000. BNP Paribas Financial Markets purchased a new position in shares of Jyong Biotech in the third quarter valued at $67,000. Millennium Management LLC increased its stake in Jyong Biotech by 209.4% during the 4th quarter. Millennium Management LLC now owns 40,258 shares of the company's stock worth $159,000 after buying an additional 27,245 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in Jyong Biotech by 19.6% in the 4th quarter. Geode Capital Management LLC now owns 64,382 shares of the company's stock worth $254,000 after buying an additional 10,538 shares in the last quarter.

About Jyong Biotech

(Get Free Report)

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers' health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.

Further Reading

• Five stocks we like better than Jyong Biotech
• REVEALED: Something Big Happening Behind White House Doors
• ALERT: Drop these 5 stocks before the market opens tomorrow!
• Elon Musk: This Could Turn $100 into $100,000
• Read this or regret it forever
• The Next Commodity Crunch (bigger than oil?)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Jyong Biotech Right Now?

Before you consider Jyong Biotech, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jyong Biotech wasn't on the list.

While Jyong Biotech currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here